Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: A prospective randomized trial

W. Scheithauer, A. Cortelezzi, E. Fritz, I. Kuhrer, E. Polli, L. Baldini, H. Ludwig

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-α-2C (rIFN-α-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26% minor responses, while 35 and 47% of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-α-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.

Original languageEnglish
Pages (from-to)109-115
Number of pages7
JournalJournal of Biological Response Modifiers
Volume8
Issue number2
Publication statusPublished - 1989

Fingerprint

Melphalan
Vincristine
Prednisone
Combination Drug Therapy
Multiple Myeloma
Cyclophosphamide
Interferons
Poisons
Therapeutics
Drug Therapy
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma : A prospective randomized trial. / Scheithauer, W.; Cortelezzi, A.; Fritz, E.; Kuhrer, I.; Polli, E.; Baldini, L.; Ludwig, H.

In: Journal of Biological Response Modifiers, Vol. 8, No. 2, 1989, p. 109-115.

Research output: Contribution to journalArticle

@article{2ba4eb39c09c4cbb964b94657a40dcaf,
title = "Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: A prospective randomized trial",
abstract = "Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-α-2C (rIFN-α-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67{\%} responses and 26{\%} minor responses, while 35 and 47{\%} of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-α-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.",
author = "W. Scheithauer and A. Cortelezzi and E. Fritz and I. Kuhrer and E. Polli and L. Baldini and H. Ludwig",
year = "1989",
language = "English",
volume = "8",
pages = "109--115",
journal = "Journal of Biological Response Modifiers",
issn = "0732-6580",
publisher = "Raven Press",
number = "2",

}

TY - JOUR

T1 - Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma

T2 - A prospective randomized trial

AU - Scheithauer, W.

AU - Cortelezzi, A.

AU - Fritz, E.

AU - Kuhrer, I.

AU - Polli, E.

AU - Baldini, L.

AU - Ludwig, H.

PY - 1989

Y1 - 1989

N2 - Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-α-2C (rIFN-α-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26% minor responses, while 35 and 47% of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-α-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.

AB - Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-α-2C (rIFN-α-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26% minor responses, while 35 and 47% of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-α-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.

UR - http://www.scopus.com/inward/record.url?scp=0024580635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024580635&partnerID=8YFLogxK

M3 - Article

C2 - 2659740

AN - SCOPUS:0024580635

VL - 8

SP - 109

EP - 115

JO - Journal of Biological Response Modifiers

JF - Journal of Biological Response Modifiers

SN - 0732-6580

IS - 2

ER -